Orchid Pharma Quarterly Results for Trading Insights
In Mar 2026, Orchid Pharma (ORCHPHARMA) reported revenue ₹376 Cr and net profit ₹26 Cr — revenue +56.0% YoY. View ORCHPHARMA 52-week chart for the annual high/low range and current price position.
ORCHPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Orchid Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse Orchid Pharma ownership structure to track promoter, FII and institutional holdings.
- Revenue of ₹376 Cr in Mar 2026 (+22.9% vs Jun 2026, +56.0% vs Mar 2025)
- Net Profit of ₹26 Cr in Mar 2026 (+766.7% vs Jun 2026, +18.2% vs Mar 2025)
- EBITDA of ₹38 Cr in Mar 2026 (+137.5% vs Jun 2026)
- Operating Margin of 8.0% in Mar 2026 (+3.0pp vs Jun 2026)
- Earnings Per Share of ₹4.31 in Mar 2026 (+698.1% vs Jun 2026)
Orchid Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ORCHPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 376 | 306 | 204 | 241 | 275 | 22.9% | 56.0% |
| Net Profit (₹ Cr) | 26 | 3 | -6 | 22 | -6 | - | - |
| EBITDA (₹ Cr) | 38 | 16 | 9 | 32 | 6 | - | - |
| EPS (₹) | 4.31 | 0.54 | -1.13 | 4.40 | -0.95 | - | - |
| Operating Margin (%) | 8.0% | 5.0% | -1.0% | 12.0% | -2.0% | - | - |
ORCHPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Orchid Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Orchid Pharma stock price NSE.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ORCHPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Orchid Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores